Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of skin conditions that cause constant inflammation and scaling of the skin. People with PRP have reddish, scaly patches that may occur everywhere on the body, or only on certain areas. Some people with PRP also develop thickened skin on the underside of the hands and feet (palmoplantar keratoderma), various nail abnormalities, and/or thinning of the hair. There are several types of PRP classified by age when symptoms begin, body areas involved, and whether other conditions are present. This condition occurs in adults (adult onset PRP) as well as children (juvenile onset PRP).
Biomarker and diagnostic research for pityriasis rubra pilaris has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE4, 1 PHASE2. Research is primarily sponsored by academic and government institutions.
108 publications have been identified in PubMed for pityriasis rubra pilaris. Research spans Case Report / Case Series (46%), Review / Meta-Analysis (22%), and Other (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 48 | 46% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:46 AM UTC
Genetic and Rare Diseases Info Center
Research summaries |
23 |
22% |
Other research | 19 | 18% |
Disease patterns and progression | 5 | 5% |
New treatment approaches | 4 | 4% |
Laboratory research | 3 | 3% |
Testing and diagnosis research | 1 | 1% |
Clinical study results | 1 | 1% |
Lin AJ (2026). [PMID: 42016654](https://pubmed.ncbi.nlm.nih.gov/42016654/). *Clin Case Rep*. [Case Report / Case Series]
Gaston J (2026). [PMID: 41134711](https://pubmed.ncbi.nlm.nih.gov/41134711/). *Clin Exp Dermatol*. [Review / Meta-Analysis]
Furudate S (2026). [PMID: 42183697](https://pubmed.ncbi.nlm.nih.gov/42183697/). *Eur J Dermatol*. [Review / Meta-Analysis]
Ziebart RL (2026). [PMID: 42175538](https://pubmed.ncbi.nlm.nih.gov/42175538/). *Int J Dermatol*. [Epidemiology / Natural History]
Giorgio CMR (2026). [PMID: 42190205](https://pubmed.ncbi.nlm.nih.gov/42190205/). *Dermatol Pract Concept*. [Other]
Ferreirinha A (2026). [PMID: 41539158](https://pubmed.ncbi.nlm.nih.gov/41539158/). *An Bras Dermatol*. [Gene Therapy / Novel Therapeutics]
Jin S (2026). [PMID: 41563745](https://pubmed.ncbi.nlm.nih.gov/41563745/). *JAMA Dermatol*. [Gene Therapy / Novel Therapeutics]
Colonna C (2026). [PMID: 41379524](https://pubmed.ncbi.nlm.nih.gov/41379524/). *Ital J Dermatol Venerol*. [Review / Meta-Analysis]
Subramani L (2026). [PMID: 42148331](https://pubmed.ncbi.nlm.nih.gov/42148331/). *Postepy Dermatol Alergol*. [Case Report / Case Series]
You R (2026). [PMID: 41820795](https://pubmed.ncbi.nlm.nih.gov/41820795/). *Int J Dermatol*. [Other]